Similar Search Results

Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007

Conti, Rena M.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2014

estimated prices of these drug undergoing LOE fall with generic entry. Second, we estimate reduced form random effects models of … utilization subsequent to LOE. We observe substantial price erosion after generic entry; average monthly price declines appear to … entry, but this result appears to be largely driven by oral drugs. We discuss second-best welfare consequences of these …

Persistent link: https://www.econbiz.de/10010950850

The Effect of FDA Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts

Conti, Rena M.; Huskamp, Haiden A.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2011

The US Food and Drug Administration (FDA) expends considerable efforts in regulating medications approved for use. Yet the impact of medication labeling changes on brand pharmaceutical products, and whether and what firms do to respond to increased information regarding the safety and efficacy...

Persistent link: https://www.econbiz.de/10009325511

Pricing and Reimbursement in U.S. Pharmaceutical Markets

Berndt, Ernst R.; Newhouse, Joseph P. - National Bureau of Economic Research (NBER) - 2010

comment on very recent developments concerning the entry of large retailers such as Wal-Mart into domains traditionally …

Persistent link: https://www.econbiz.de/10008531891

Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation

Berndt, Ernst R.; Aitken, Murray L. - National Bureau of Economic Research (NBER) - 2010

following initial generic entry and by 24 months to 65, in 2009 the comparable generic price indexes are 68 and 27, respectively … patent has expired. Across all nine therapeutic areas, at 24 months post-generic entry, the weighted mean reduction in …

Persistent link: https://www.econbiz.de/10008682661

Costs, Institutional Mobility Barriers, and Market Structure: Advertising Agencies as Multiproduct Firms

Silk, Alvin J.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 1994

low fixed costs and minimal entry barriers, both media-specific scale and scope economies are available and can be …

Persistent link: https://www.econbiz.de/10005248932

International Health Economics

Philipson, Tomas; Egan, Mark - National Bureau of Economic Research (NBER) - 2013

Perhaps because health care is a local service sector, health economists have paid little attention to international linkages between domestic health care economies. However, the growth in domestic health care sectors is often attributed to medical innovations whose returns are earned worldwide....

Persistent link: https://www.econbiz.de/10010950973

Health Care Adherence and Personalized Medicine

Philipson, Tomas; Egan, Mark - National Bureau of Economic Research (NBER) - 2014

Non-adherence in health care results when a patient does not initiate or continue care that a provider has recommended. Previous research identifies non-adherence as a major source of waste in US health care, totaling approximately 2.3% of GDP, and have proposed a plethora of interventions to...

Persistent link: https://www.econbiz.de/10011274532

Is the Obesity Epidemic a Public Health Problem? A Decade of Research on the Economics of Obesity

Philipson, Tomas; Posner, Richard A. - National Bureau of Economic Research (NBER) - 2008

The world-wide and ongoing rise in obesity has generated enormous popular interest and policy concern in developing countries, where it is rapidly becoming the major public health problem facing such nations. As a consequence, there has been a rapidly growing field of economic analysis of the...

Persistent link: https://www.econbiz.de/10005248898

Is the Food and Drug Administration Safe and Effective?

Philipson, Tomas; Sun, Eric - National Bureau of Economic Research (NBER) - 2007

In the United States, drug safety and efficacy are primarily regulated by the Food and Drug Administration (FDA) and the legal system, which gives manufacturers large incentives to produce safe drugs and provide proper warnings for side effects, since patients can sue manufacturers that provide...

Persistent link: https://www.econbiz.de/10005084722

Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process

Philipson, Tomas; Berndt, Ernst R.; Gottschalk, Adrian H. B. - National Bureau of Economic Research (NBER) - 2004

Congress enacted and renewed the Prescription Drug User Fee Acts (PDUFA) in 1992, and renewed it in 1997 and 2002, mandating FDA performance goals in reviewing and acting on drug applications within specified time periods. In turn, the FDA was permitted to levy user fees on drug sponsors...

Persistent link: https://www.econbiz.de/10005084928